Q-omics provides the consensus-scored SCN2A profile across patient tissues and cancer cell-line models. SCN2A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SCN2A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SCN2A RNA expression shows 15,082 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UCEC, KIRC, and PCPG as cancer lineages where SCN2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN2A survival associations across molecular data types. SCN2A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN2A RNA expression–survival associations across cancer types. High SCN2A expression shows unfavorable associations in UCEC, HNSC, UVM, KIRC and BLCA, but favorable associations in PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SCN2A RNA expression.
This table summarizes SCN2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCN2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN2A shows lower tumor expression in KIRC, KICH, BRCA, UCEC and KIRP and higher tumor expression in HNSC. The KIRC box plot shows higher SCN2A RNA expression in normal versus tumor tissue (log2 FC = −1.694, t-test p < 0.001).
This table shows molecular features associated with SCN2A in patient tissues and cancer cell lines. In patient samples, SCN2A shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
